165 related articles for article (PubMed ID: 15937499)
1. Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma.
Wulf GG; Hasenkamp J; Jung W; Chapuy B; Truemper L; Glass B
Bone Marrow Transplant; 2005 Aug; 36(3):271-3. PubMed ID: 15937499
[No Abstract] [Full Text] [Related]
2. Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome.
Novitzky N; Thomas V; du Toit C
Cytotherapy; 2008; 10(1):45-53. PubMed ID: 18202974
[TBL] [Abstract][Full Text] [Related]
3. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
Peggs KS; Sureda A; Qian W; Caballero D; Hunter A; Urbano-Ispizua A; Cavet J; Ribera JM; Parker A; Canales M; Mahendra P; Garcia-Conde J; Milligan D; Sanz G; Thomson K; Arranz R; Goldstone AH; Alvarez I; Linch DC; Sierra J; Mackinnon S;
Br J Haematol; 2007 Oct; 139(1):70-80. PubMed ID: 17854309
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma.
Chanan-Khan A; Islam T; Alam A; Miller KC; Gibbs J; Barcos M; Czuczman MS; Paplham P; Hahn T; McCarthy P
Leuk Lymphoma; 2004 Aug; 45(8):1673-5. PubMed ID: 15370223
[TBL] [Abstract][Full Text] [Related]
6. CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors.
Popat U; Carrum G; May R; Lamba R; Krance RA; Heslop HE; Brenner MK
Bone Marrow Transplant; 2005 Jun; 35(12):1127-32. PubMed ID: 15834432
[TBL] [Abstract][Full Text] [Related]
7. Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL).
Morris E; Mackinnon S
Transfus Apher Sci; 2005 Feb; 32(1):73-83. PubMed ID: 15737876
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma patients.
Coiffier B
Haematologica; 1999 Jun; 84 Suppl EHA-4():14-8. PubMed ID: 10907457
[No Abstract] [Full Text] [Related]
9. Chimerism does not predict for outcome after alemtuzumab based conditioning.
Michaelis L; Lin S; Joseph L; Artz AS; Kline J; Pollyea D; Stock W; Rich E; Collins-Jones D; Casey B; Del Cerro P; van Besien K
Bone Marrow Transplant; 2007 Jul; 40(2):181. PubMed ID: 17502895
[No Abstract] [Full Text] [Related]
10. High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma.
Buser AS; Heim D; Bucher C; Tichelli A; Gratwohl A; Passweg JR
Bone Marrow Transplant; 2004 May; 33(10):1011-4. PubMed ID: 15064693
[TBL] [Abstract][Full Text] [Related]
11. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
Mandigers CM; Verdonck LF; Meijerink JP; Dekker AW; Schattenberg AV; Raemaekers JM
Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270
[TBL] [Abstract][Full Text] [Related]
12. T cell depletion of allogeneic stem cell grafts with anti-CD 52 monoclonal antibodies: the Ulm experience from 1983-1999.
Bunjes D
Transfus Sci; 2000 Oct; 23(2):151-62. PubMed ID: 11035276
[No Abstract] [Full Text] [Related]
13. Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience.
Escalón MP; Stefanovic A; Venkatraman A; Pereira D; Santos ES; Goodman M; Byrnes JJ; Fernandez HF
Bone Marrow Transplant; 2009 Jul; 44(2):89-96. PubMed ID: 19169287
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
O'Brien SM; Kantarjian HM; Thomas DA; Cortes J; Giles FJ; Wierda WG; Koller CA; Ferrajoli A; Browning M; Lerner S; Albitar M; Keating MJ
Cancer; 2003 Dec; 98(12):2657-63. PubMed ID: 14669286
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
[TBL] [Abstract][Full Text] [Related]
16. Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation.
Hill QA; Hill A; Collyns TA; Pearce RM; Cook G
Bone Marrow Transplant; 2008 Apr; 41(8):749-51. PubMed ID: 18195685
[No Abstract] [Full Text] [Related]
17. Pharmacokinetics of alemtuzumab after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab with or without CD52-positive malignancies.
Oshima K; Kanda Y; Nakahara F; Shoda E; Suzuki T; Imai Y; Watanabe T; Asai T; Izutsu K; Ogawa S; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2006 Nov; 81(11):875-9. PubMed ID: 16862551
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.
Gómez-Almaguer D; Ruiz-Argüelles GJ; del Carmen Tarín-Arzaga L; González-Llano O; Gutiérrez-Aguirre H; Cantú-Rodríguez O; Jaime-Pérez J; Carrasco-Yalán A; Giralt S
Biol Blood Marrow Transplant; 2008 Jan; 14(1):10-5. PubMed ID: 18158956
[TBL] [Abstract][Full Text] [Related]
19. Role of hematopoietic stem cell transplantation in the treatment of non-Hodgkin's lymphoma.
Bierman PJ; Phillips GL
Cancer Treat Res; 2009; 144():357-97. PubMed ID: 19779882
[No Abstract] [Full Text] [Related]
20. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.
Corradini P; Dodero A; Zallio F; Caracciolo D; Casini M; Bregni M; Narni F; Patriarca F; Boccadoro M; Benedetti F; Rambaldi A; Gianni AM; Tarella C
J Clin Oncol; 2004 Jun; 22(11):2172-6. PubMed ID: 15169805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
